DaVita Inc. vs Eli Lilly & Co.
DVA vs LLY — side-by-side comparison from reported financials. DVA leads 4, LLY leads 6 of 10 comparable metrics.
DaVita Inc.
DVA · Healthcare
$179.25+1.26%Strained
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | DVA | LLY |
|---|---|---|
| Price | $179.25 | $1 177.20 |
| Market cap | $11.4B | $1.05T |
| Revenue (TTM) | $14.0B | $79.7B |
| Revenue growth | +5.5% | +31.7% |
| Net margin | 6.0% | 33.5% |
| Free cash flow | $1.61B | $18.2B |
| Net cash (debt) | ($9.57B) | ($35.2B) |
| 1-year price return | +41.8% | +37.6% |
| P/E | 13.5 | 41.6 |
| P/E vs own history (cheap-side %) | 54% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 181% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 8 of 10 | 11 of 10 |
| Employees | 78,000 | 50,000 |
Full résumé-style profiles: DVA CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.